REM1
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
05/25/2026
Back to search
Official data from USPTO
TANVEX PHARMACEUTICALS
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
TANVEX PHARMACEUTICALS
ST13
US500000087323903Class
5
Filing
87323903
Registration
6358664
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
62
Latest update
05/26/2026
Trademark type
Word
Nice classes
5
Filing date
02/03/2017
Registration date
05/25/2021
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
05/25/2021
Last transaction
05/26/2026
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Intent to use
Drawing code
4
Owner type
03
Owner location
Grand Cayman, KY
Examiner
SCHMIDT, JOHN JOSEPH
Law office
N10
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
Tanvex BioPharma, Inc.
Representatives
Dyan M. House Baker & McKenzie LLP
Technical classification
Nice Classes
Class 5
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Anti-arthritis preparations; anti-inflammatory agent; anticancer drug; antirheumatic preparations; medicines for human purposes for treating diseases and medical conditions in the fields of dermatologygastroenterologyhematologyinfectious diseaseoncologyrheumatologyneutropeniabreast cancergastric cancercolorectal cancerlung cancerglioblastomacarcinomaarthritisCrohn's diseaseplaque psoriasisasthmachronic idiopathic urticariapararoxysmal nocturnal hemoglobinuriaatypical hemolytic uremic syndrome; western medicines for treating diseases and medical conditions in the fields of dermatologygastroenterologyhematologyinfectious diseaseoncologyrheumatologyneutropeniabreast cancergastric cancercolorectal cancerlung cancerglioblastomacarcinomaarthritisCrohn's diseaseplaque psoriasisasthmachronic idiopathic urticariapararoxysmal nocturnal hemoglobinuriaatypical hemolytic uremic syndrome; medicinal agent for human usemedicinal herbal preparations; biological preparations for medical purposes for treating diseases and medical conditions in the fields of dermatologygastroenterologyhematologyinfectious diseaseoncologyrheumatologyneutropeniabreast cancergastric cancercolorectal cancerlung cancerglioblastomacarcinomaarthritisCrohn's diseaseplaque psoriasisasthmachronic idiopathic urticariapararoxysmal nocturnal hemoglobinuriaatypical hemolytic uremic syndrome; haematogenblood substitutes for human use; chemical preparations for medical purposes for treating diseases and medical conditions in the fields of dermatologygastroenterologyhematologyinfectious diseaseoncologyrheumatologyneutropeniabreast cancergastric cancercolorectal cancerlung cancerglioblastomacarcinomaarthritisCrohn's diseaseplaque psoriasisasthmachronic idiopathic urticariapararoxysmal nocturnal hemoglobinuriaatypical hemolytic uremic syndrome; pharmaceutical drugs for treating diseases and medical conditions in the fields of dermatologygastroenterologyhematologyinfectious diseaseoncologyrheumatologyneutropeniabreast cancergastric cancercolorectal cancerlung cancerglioblastomacarcinomaarthritisCrohn's diseaseplaque psoriasisasthmachronic idiopathic urticariapararoxysmal nocturnal hemoglobinuriaatypical hemolytic uremic syndrome; pharmaceutical preparations for treating diseases and medical conditions in the fields of dermatologygastroenterologyhematologyinfectious diseaseoncologyrheumatologyneutropeniabreast cancergastric cancercolorectal cancerlung cancerglioblastomacarcinomaarthritisCrohn's diseaseplaque psoriasisasthmachronic idiopathic urticariapararoxysmal nocturnal hemoglobinuriaatypical hemolytic uremic syndrome
Publications
History of USPTO decisions and trademark events.
62 publications found
R.PR
REGISTERED-PRINCIPAL REGISTER
05/25/2021
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
03/09/2021
PUBO
PUBLISHED FOR OPPOSITION
03/09/2021
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
02/17/2021
OTHE
CASE RETURNED TO EXAMINATION
02/03/2021
ATRQ
ATTORNEY REVIEW/DECISION ON AMENDMENT REQUIRED
02/02/2021
IUCN
NOTICE OF ALLOWANCE CANCELLED
01/04/2021
APET
ASSIGNED TO PETITION STAFF
01/04/2021
PCBG
PETITION TO DIRECTOR - CHANGE BASIS - GRANTED
01/04/2021
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
12/18/2020
EWAF
TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
12/18/2020
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
12/18/2020
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
12/18/2020
TPAD
TEAS PETITION TO AMEND BASIS RECEIVED
12/18/2020
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
07/23/2020
EX5G
SOU EXTENSION 5 GRANTED
07/22/2020
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
07/22/2020
EXT5
SOU EXTENSION 5 FILED
07/01/2020
EEXT
SOU TEAS EXTENSION RECEIVED
07/01/2020
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
07/01/2020
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
07/01/2020
EWAF
TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
07/01/2020
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
07/01/2020
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
07/01/2020
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
07/01/2020
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
12/31/2019
EX4G
SOU EXTENSION 4 GRANTED
12/27/2019
EXT4
SOU EXTENSION 4 FILED
12/27/2019
EEXT
SOU TEAS EXTENSION RECEIVED
12/27/2019
DOCK
ASSIGNED TO EXAMINER
07/08/2019
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
06/07/2019
EX3G
SOU EXTENSION 3 GRANTED
06/05/2019
EXT3
SOU EXTENSION 3 FILED
06/05/2019
EEXT
SOU TEAS EXTENSION RECEIVED
06/05/2019
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
12/26/2018
EX2G
SOU EXTENSION 2 GRANTED
12/24/2018
EXT2
SOU EXTENSION 2 FILED
12/24/2018
EEXT
SOU TEAS EXTENSION RECEIVED
12/24/2018
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
05/04/2018
EX1G
SOU EXTENSION 1 GRANTED
05/02/2018
EXT1
SOU EXTENSION 1 FILED
05/02/2018
EEXT
SOU TEAS EXTENSION RECEIVED
05/02/2018
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
05/02/2018
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
01/02/2018
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
11/07/2017
PUBO
PUBLISHED FOR OPPOSITION
11/07/2017
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
10/18/2017
PREV
LAW OFFICE PUBLICATION REVIEW COMPLETED
10/05/2017
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
10/02/2017
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
09/23/2017
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
09/23/2017
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
09/20/2017
GPRN
NOTIFICATION OF PRIORITY ACTION E-MAILED
05/06/2017
GPRA
PRIORITY ACTION E-MAILED
05/06/2017
CPRA
PRIORITY ACTION WRITTEN
05/06/2017
DOCK
ASSIGNED TO EXAMINER
04/29/2017
AMPX
PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED
03/30/2017
ALIE
ASSIGNED TO LIE
03/10/2017
PARI
TEAS VOLUNTARY AMENDMENT RECEIVED
02/23/2017
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
02/08/2017
NWAP
NEW APPLICATION ENTERED
02/07/2017
Continuous trademark protection
Get notified about every new filing that threatens TANVEX PHARMACEUTICALS or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.